Oncology News
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Oncology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain Management/
    Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
brca1  brca1
prostate-specific antigen  prostate-specific antigen
sclc  sclc
fobt  fobt
egd  egd
bmi  bmi
dysplasia  dysplasia
hematologic  hematologic
ovarian  ovarian
hcc  hcc
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Outcomes of patients with stage III non-small cell lung cancer treated with chemotherapy and radiation with and without surgery
Caglar HB et al. - In a study to identify the factors associated with improved outcome after treatment for stage III non-small cell lung cancer (NSCLC), it seems that stage at the time of treatment (stage IIIA vs stage IIIB) and use of surgery were the only factors associated with improved outcome.

Methods
  • A retrospective review of stage III NSCLC pts was done.
  • Pts were followed for toxicity, local and distant failure, and overall survival (OS).
  • Multivariate Cox logistic regression analysis was used to determine factors associated with treatment outcome.

Results
  • 144 pts received concurrent chemoradiation (CRT) for stage III NSCLC.
  • 80 of 144 pts were men (56%), and median age was 61 yrs.
  • 62 pts (43%) had stage IIIA NSCLC, and 82 pts (57%) had stage IIIB NSCLC.
  • Radiotherapy (RT) was given concurrently with chemotherapy to all pts; 100 pts (69%) received CRT without surgery, and 44 pts (31%) received with neoadjuvant CRT followed by surgical resection.
  • Median RT dose was 60 grays (Gy).
  • Median follow-up was 15 mos, median potential follow-up was 37 mos, and median OS was 22 mos.
  • 1-yr and 2-yr survival rates were 68% and 47%, respectively.
  • Among the 44 pts who underwent resection, median survival was 61 mos, and 2-yr survival rate was 73%.
  • On multivariate analysis, stage at the time of treatment (stage IIIA vs stage IIIB) and use of surgery were the only factors associated with improved outcome.
[more...]
Sponsor

Read a Different Specialty

Oncology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Oncology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.